- The use of niraparib in the treatment of ovarian cancer2023 | First Faculty of Medicine
- Niraparib2021 | First Faculty of Medicine
- Niraparib expands the availability of maintenance therapy in patients with advanced high-grade ovarian cancer2022 | Faculty of Medicine in Pilsen
- Niraparib as maintenance therapy after primary treatment of ovarian cancer - a case report2023 | First Faculty of Medicine
- Niraparib in Patients with Newly Diagnosed Advanced Ovarian CancerPublication without faculty affiliation
- Niraparib and Abiraterone Acetate for Metastatic Castration-Resistant Prostate CancerPublication without faculty affiliation
- Zkušenosti s léčbou niraparibem u pacientek s pokročilým karcinomem ovaria2022 | Third Faculty of Medicine
- Niraparib v udržovací léčbě pokročilého karcinomu vaječníků2022 | First Faculty of Medicine
- Niraparib - nová naděje v léčbě ovariálního karcinomu2023 | Third Faculty of Medicine
- Udržovací léčba niraparibem u pacientky s karcinomem vaječníků2023 | First Faculty of Medicine
- AGO-OVAR 28/ENGOT-ov57. Niraparib alone versus niraparib in combination with bevacizumab in patients with carboplatin-taxane-based chemotherapy in advanced ovarian cancer: a multicenter randomized phase III trial2023 | First Faculty of Medicine
- Randomized phase III trial on niraparib-TSR-042 (dostarlimab) versus physician's choice chemotherapy in recurrent ovarian, fallopian tube, or primary peritoneal cancer patients not candidate for platinum retreatment: NItCHE trial (MITO 33)2021 | Publication without faculty affiliation
- Současné možnosti léčby karcinomu vaječníků2021 | First Faculty of Medicine